Mirghasemi Alireza, Taheriazam Afshin, Karbasy Seyyed Hasan, Torkaman Ali, Shakeri Mohammadreza, Yahaghi Emad, Mokarizadeh Aram
Department of Orthopedics, Qom University of Medical Sciences, Qom, Iran.
Department of Orthopedics Surgery, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Cancer Cell Int. 2015 Sep 17;15:86. doi: 10.1186/s12935-015-0237-6. eCollection 2015.
MicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the present study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of these miRNAs.
The expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis.
Our findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteosarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; P = 0.01). Furthermore, Kaplan-Meier survival analysis and log-rank test showed that the low expressions of miR-133a and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox proportional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of overall survival of patients.
These results suggest that decreased miR-133a and miR-539 expressions may participate in the progression of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progression and prognosis of osteosarcoma.
微小RNA（miRNA）在癌症的发生和发展中起关键作用。本研究的目的是确定骨肉瘤患者中miR-133a和miR-539的表达水平，并进一步研究这些miRNA的临床病理及预后价值。
采用qRT-PCR检测miR-133a和miR-539的表达水平。分析miRNA表达与各种临床病理特征之间的关联。采用Kaplan-Meier法确定生存率，并通过log-rank检验进行组间统计学分析。通过多因素Cox回归分析评估生存数据。
我们的研究结果显示，与相邻正常骨组织相比，临床骨肉瘤组织中miR-133a的表达显著降低。与相邻正常组织相比，临床骨肉瘤组织中miR-539的表达水平降低。miR-133a和miR-539的低表达与晚期TNM分期（P = 0.002；P = 0.001）以及转移或复发（P = 0.001；P = 0.01）显著相关。此外，Kaplan-Meier生存分析和log-rank检验表明，miR-133a和miR-539的低表达与骨肉瘤患者总生存期的降低相关。多因素Cox比例风险模型显示，miR-133a和miR-539表达降低（P = 0.007；P = 0.02）、TNM分期（P = 0.001；P = 0.002）以及转移或复发（P = 0.005；P = 0.026）是患者总生存期的独立预后标志物。
这些结果表明，miR-133a和miR-539表达降低可能参与了骨肉瘤的进展。总之，这些结果表明miR-133a和miR-539可能在骨肉瘤的进展和预后中发挥作用。
Zotero 插件
